156 related articles for article (PubMed ID: 30655614)
1. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
Eggemann H; Bernreiter AL; Reinisch M; Loibl S; Taran FA; Costa SD; Ignatov A
Br J Cancer; 2019 Feb; 120(3):301-305. PubMed ID: 30655614
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
3. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
Nolan L; Darby A; Boleti K; Simmonds P
Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients.
Koc M; Polat P; Suma S
Radiother Oncol; 2002 Aug; 64(2):171-5. PubMed ID: 12242127
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group.
McDonald CC; Alexander FE; Whyte BW; Forrest AP; Stewart HJ
BMJ; 1995 Oct; 311(7011):977-80. PubMed ID: 7580638
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
[TBL] [Abstract][Full Text] [Related]
10. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
12. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.
Debourdeau P; Espié M; Chevret S; Gligorov J; Elias A; Dupré PF; Desseaux K; Kalidi I; Villiers S; Giachetti S; Frere C; Farge D
Cancer Med; 2017 Nov; 6(11):2732-2744. PubMed ID: 28980454
[TBL] [Abstract][Full Text] [Related]
14. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
[TBL] [Abstract][Full Text] [Related]
15. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
16. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
Pritchard KI; Paterson AH; Paul NA; Zee B; Fine S; Pater J
J Clin Oncol; 1996 Oct; 14(10):2731-7. PubMed ID: 8874334
[TBL] [Abstract][Full Text] [Related]
17. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
18. [Tolerance of Tamoxifen as an adjuvant therapy and long-term follow up of 55 premenopausal breast cancer women, cared for at the Institut de cancérologie de Lorraine, treated with Tamoxifen].
Sebaoun P; Frederic M; Weryha G; Hamdaoui SE; Salleron J; Lesur A
Bull Cancer; 2019 Dec; 106(12S1):S75-S100. PubMed ID: 32008741
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.
Hong JH; Ha KS; Jung YH; Won HS; An HJ; Lee GJ; Kang D; Park JC; Park S; Byun JH; Suh YJ; Kim JS; Park WC; Jung SS; Park IY; Chung SM; Woo IS
Cancer Res Treat; 2016 Oct; 48(4):1389-1398. PubMed ID: 27121722
[TBL] [Abstract][Full Text] [Related]
20. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
